** Shares of drug developer Altimmune ALT.O rose nearly 3% in extended trading before paring gains
** Company says that it is planning to test its experimental weight-loss drug, pemvidutide, as a treatment for alcohol use disorder and alcohol-associated liver disease
** Plans to begin a mid-stage trial in alcohol use disorder for pemvidutide in Q2 and another mid-stage trial for alcohol-related liver disease in Q3
** Co's drug, pemvidutide, has shown to help patients reduce their weight by 15.6% on average in a mid-stage trial
** As of the last close, stock down 27.9% YTD
(Reporting by Pooja Menon in Bengaluru)
((Pooja.Menon@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。